Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AFM28 |
| Synonyms | |
| Therapy Description |
AFM28 is a bispecific innate cell engager that redirects CD16A-positive NK cells towards CD123 (IL3RA)-positive tumor cells, potentially leading to antibody-dependent cellular cytotoxicity and decreased tumor growth (PMID: 40841539). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AFM28 | AFM-28|AFM 28 | CD123 (IL3RA) Antibody 14 | AFM28 is a bispecific innate cell engager that redirects CD16A-positive NK cells towards CD123 (IL3RA)-positive tumor cells, potentially leading to antibody-dependent cellular cytotoxicity and decreased tumor growth (PMID: 40841539). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05817058 | Phase I | AFM28 | First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Terminated | FRA | ESP | 0 |